Short answer
Beam Therapeutics Inc. (BEAM) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Beam Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial details and management commentary
Item EX-99.1 · Exhibit EX-99.1
- BEAM-302 entered global pivotal dosing, advancing AATD toward potential accelerated approval and creating a major 2026 clinical catalyst
- Risto-cel dosing completed in adult and adolescent BEACON patients, with updated data and potential BLA submission by year-end 2026
- Cash, equivalents and marketable securities totaled $1.2B, with expected funding into mid-2029 including $200M Sixth Street draw
- Second-quarter net loss widened to $122.7M, or $1.18 per share, from $102.1M, or $1.00 per share
- BEAM-304 received FDA IND clearance, enabling Phase 1/2 testing in PKU and expanding Beam’s liver-targeted pipeline beyond AATD
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Beam Therapeutics Inc. 8-K filings
Get the next BEAM 8-K as it lands
Follow BEAM for push alerts, or ask the research agent what this filing means.